13 results
POS AM
LSB
LakeShore Biopharma Co., Ltd
23 Jan 24
Prospectus update (post-effective amendment)
4:18pm
limitations may hinder YS Group’s ability to recoup its investment in its marketed product and/or one or more product candidates, even if they obtain
424B3
LSB
LakeShore Biopharma Co., Ltd
15 Aug 23
Prospectus supplement
8:00am
of the drug in that country. Adverse pricing limitations may hinder YS Group’s ability to recoup its investment in its marketed product and/or one or more
POS AM
LSB
LakeShore Biopharma Co., Ltd
8 Aug 23
Prospectus update (post-effective amendment)
4:06pm
from the sale of the drug in that country. Adverse pricing limitations may hinder YS Group’s ability to recoup its investment in its marketed product
20-F
l8g5bc
26 Jul 23
Annual report (foreign)
4:02pm
424B3
2a3xnhe82
5 Jun 23
Prospectus supplement
4:03pm
F-1/A
00d9zfgca4x2
12 May 23
Registration statement (foreign) (amended)
4:05pm
F-1
zhj9asr 941436um7mv0
12 Apr 23
Registration statement (foreign)
8:49am
F-4
etw2n8vk
28 Dec 22
Registration of securities (foreign)
6:58am
DRS/A
pfxlej19yyrdhrf
7 Dec 22
Draft registration statement (amended)
12:00am
DRS/A
y4vkdkx ww
14 Nov 22
Draft registration statement (amended)
12:00am
DRS
eru3bkzc
3 Oct 22
Draft registration statement
12:00am
- Prev
- 1
- Next